Cybin sees third-quarter loss on R&D costs, advances clinical programs
Cybin pushes forward with Phase 3 depression trials after narrowing its loss, while securing a $100M funding program.
The post Cybin sees third-quarter loss on R&D costs, advances clinical programs appeared first on Green Market Report.
